Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday

Cadrenal Therapeutics (NASDAQ:CVKD) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

Cadrenal Therapeutics Stock Performance

Shares of CVKD stock opened at $8.30 on Thursday. Cadrenal Therapeutics has a fifty-two week low of $4.91 and a fifty-two week high of $20.39. The stock’s fifty day moving average is $7.11 and its two-hundred day moving average is $10.37. The firm has a market capitalization of $19.42 million, a P/E ratio of -1.04 and a beta of 1.04.

Insiders Place Their Bets

In other Cadrenal Therapeutics news, CFO Matthew K. Szot sold 9,933 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 26.09% of the company’s stock.

Institutional Investors Weigh In On Cadrenal Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Cadrenal Therapeutics during the third quarter worth about $103,000. DRW Securities LLC acquired a new stake in shares of Cadrenal Therapeutics during the fourth quarter worth about $171,000. Finally, Citadel Advisors LLC purchased a new position in shares of Cadrenal Therapeutics in the third quarter valued at approximately $274,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cadrenal Therapeutics has a consensus rating of “Hold” and an average price target of $32.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.